Immunic, Inc

1200 Avenue of the Americas, Suite 200
New York, NY 10036, USA

Phone: +49 89 2080 477 00
Email: info@imux.com

Immunic AG

Lochhamer Schlag 21
82166 Gräfelfing, Germany

Phone: +49 89 2080 477 00
Email: info@imux.com

Jessica

February 17, 2021

Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial

– Clinical Activity of IMU-838 Confirmed Based on Multiple Secondary Endpoints, Including...

Read More
February 11, 2021

Immunic, Inc. to Participate in the SVB Leerink 10th Annual Global Healthcare Conference on February 25

NEW YORK, February 11, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company...

Read More
January 8, 2021

Development of Innovative COVID-19 Therapies Needs Additional Public Funding to Help Patients in the Short-Term (in German Only)

Entwicklung innovativer COVID-19-Medikamente bedarf weitergehender öffentlicher Förderung, um Patienten schnell zu helfen...

Read More
January 5, 2021

Immunic, Inc. to Participate in Investor Conferences in January

– Management Provides Update on Timing of Data for IMU-838 in Primary...

Read More
December 14, 2020

Immunic, Inc. Added to NASDAQ Biotechnology Index

NEW YORK, December 14, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company...

Read More
December 2, 2020

BEAT-COV Initiative Requests Support for the Development and Production of New, Innovative COVID-19 Therapies (in German Only)

Initiative BEAT-COV fordert Unterstützung für Entwicklung und Produktion neuer, innovativer COVID-19-Medikamente Sichere...

Read More
November 24, 2020

Immunic, Inc. to Participate in Investor Conferences in December

NEW YORK, November 24, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company...

Read More
November 17, 2020

Immunic, Inc. Announces Formation of Scientific-Medical Advisory Board

– Initial Appointments Include Internationally Recognized Experts: Fred D. Lublin, M.D.; Bruce E....

Read More
November 10, 2020

Immunic, Inc. to Participate in Investor and Scientific Conferences in November

NEW YORK, November 10, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company...

Read More
November 5, 2020

Immunic, Inc. Reports Third Quarter 2020 Financial Results and Provides Corporate Update

– Released Very Positive Phase 2 Data for IMU-838 in Relapsing-Remitting Multiple...

Read More
October 20, 2020

EIB Provides Immunic With up to €24.5 Million to Support Ongoing Development of a Potential COVID-19 Therapy

EIB Provides Immunic With up to €24.5 Million to Support Ongoing Development...

Read More
September 29, 2020

Immunic, Inc. to Participate in Scientific Conferences in October

NEW YORK, September 29, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company...

Read More
September 28, 2020

Immunic, Inc. Announces Results From Interim Safety Analysis and Recruitment Update From Its Ongoing Phase 2 CALVID-1 Trial of IMU-838 in Patients With Moderate COVID-19

NEW YORK, September 28, 2020 – Immunic, Inc. (Nasdaq: IMUX),a clinical-stage biopharmaceutical company...

Read More